Sedation and General Anesthesia in Ruminants

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Sedation and General Anesthesia in Ruminants Cynthia M. Trim, BVSc, MRCVS, DVA, DACVA Department of Veterinary Medicine and Surgery College of Veterinary Medicine University o f Missouri-Columbia Columbia, Missouri Introduction During rumination in the conscious animal, vagal activity produces reticular contraction forcing ingesta against the There is nothing magical about anesthesia for animals cardia while reflux into the pharynx is dependent upon an classed as Food Producing species. Generally, they will intact parasympathetic nervous system to the respond to anesthetic drugs in the same way as the dog or pharyngoesophageal sphincter and esophagus. Atropine cat, and satisfactory anesthesia can be accomplished with may reduce the incidence of regurgitation by reducing the same drugs that are used in small animal practice, given reticular contractions. However, the risk of regurgitation is the appropriate preparation, equipment, and time. more influenced by the relaxing effect of anesthetic drugs on However, confusion remains as to the "best" anesthetic the pharyngo-esophageal and gastro-esophageal sphincters. technique, e.g., for a bull for penile surgery or a goat for Experimental data indicate that the pharyngo-esophageal cystotomy. In a practice situation, the major drawback to sphincter is the most resistant barrier,1 but clinical the administration of an anesthetic is cost. Often the experience has demonstrated that some sedatives, especially economic value of the animal is insufficient to warrant xylazine,3 and all general anesthetic drugs depress utilization of expensive drugs or to promote acquisition of pharyngeal tone (i.e. the swallowing reflex) in varying necessary equipment; anesthetic machines, surgery tables, degrees. The most important factor, therefore, becomes the and monitoring devices. Consequently, anesthesia becomes degree of pressure inside the rumen. The most effective a question of which is the simplest, most economical, and method of maintaining low rumen pressure and decreasing safest technique that will allow surgery to be performed. It is the incidence of regurgitation is to reduce the volume of difficult to recommend specific anesthetic techniques. While rumenal contents. This can be accomplished by withholding pitfalls can be pinpointed, precautions suggested, and food for 36 hours and water for 6-8 hours prior to the pharmacological actions of drug combinations described, procedure. The adverse effects of withholding food for this the practitioner must make these choices depending on the period of time are apparently minimal in the healthy animal. value of the animal and the availability of equipment. Mitchell and Williams have reported that only a mild This article is concerned with the most frequently metabolic alkalosis occurred in sheep following 48 hours of encountered problems associated with sedation and/or starvation.2 anesthesia in ruminants and gives recommendations to Forceful regurgitation sometimes occurs on induction of reduce or eliminate the risk of these problems during general anesthesia. Typically, in a lightly anesthetized subsequent surgery or surgical procedures. Further, types patient, this occurs during intubation of the trachea. It is and effects of sedatives and general anesthetics which are probable that stimulation of the larynx causes the glottis to used routinely are also considered. close and inspiration during this time results in a strong negative intra-thoracic pressure. This pressure difference Potential Problems causes rumenal contents to enter the esophagus and initiates peristaltic waves which move the material towards the A. Regurgitation and pulmonary aspiration pharynx. Esophageal contractions are easily observed and B. Bloat, influencing adequacy of ventilation warn of impending regugitation. Alternatively, coughing, C. Inadequate oxygenation in the adult bovine stimulated by laryngeal manipulation during intubation, D. Injury in the perioperative period also may initiate regurgitation through an acute rise in A. Regurgitation. Regurgitation of rumenal contents rumenal pressure. Clinical impression suggest that a lower and subsequent pulmonary aspiration is always a potential incidence of regurgitation occurs if surgical anesthesia is hazard of heavy sedation or general anesthesia in the induced in the ruminant before endotracheal intubation is ruminant. performed. Regurgitation while an endotracheal tube is in This paper is published by permission of the Editor, California Veterinarian and the author. d Xylazine, Bayer NOVEMBER, 1981 137 scours... Easy come Easy go with Vetisulid— backed by laboratory and field experi­ ments which assure you of effec­ tive treatment against scours caused by E. coli, the most common infective organism. Vetisulid is recommended for treatment of calf scours. It’s available in 3 dosage forms— injection, oral boluses, and pow­ SQUIBB der which can be mixed with 21SN (215 mg. per ml ) milk or milk substitutes. ^ T IS U U O iw e c t iw Sullachlorpyridazine 1$*$* Withdrawal time—only 5 days ANTlBACTE^r- after the last intravenous dose, 7 days after the last oral dose. Check with your veterinarian to have the infection diagnosed L**#»iSc7 right. Then ask about the bene­ usuur Powder j iam Sulfachlorpyridazine 1 fits of going with Vetisulid. SOlDTO*1* MUlTimJ imamtvmf.ctiiOSPECIKUMANIlWCHSilM |I «801US£S WT 19 OZ {54 GRAmI Sulfachlorpyridazine (pronounced ‘Veta-sue-lid’) available only from your veterinarian SQUIBB ©1980 E.R. Squibb & Sons, Inc. 870-501 Issued: Nov. 1980 place is of little concern provided that the pharynx is cleared mismatch, 1) withhold food for 36 hours to reduce the and drained and the nasal cavity flushed prior to extubation. weight of abdominal contents on the diaphragm, 2) maintain Recommendations: To prevent or reduce regurgitation a good cardiac output and arterial blood pressure by and pulmonary aspiration, management of the ruminant avoiding large doses of sedative or tranquilizers and by under heavy sedation or general anesthesia must include 1) maintaining a light plane of general anesthesia. prior withholding of food for 36 hours and water for 6-8 Treatment: In the absence of an anesthetic machine, hours, 2) endotracheal intubation even though anesthesia is oxygen can be administered by a small stomach tube passed maintained with injectable agents, 3) positioning the head through the ventral nasal meatus or into an endotrachael with the nostrils lower than the larynx to allow free drainage tube. Adequate oxygenation can usually be maintained in of saliva and regurgitated fluid, and 4) avoid moving the the face of moderate ventilation-perfusion mismatch by animal once it is anesthetized. Regurgitation and aspiration delivering 15-25 L O 2/ minute into the pharynx or 10-15 L occurring in the anesthetized adult bovine as a result of O 2/minute into the trachea. rolling it over leaves the veterinarian liable for negligence.3 D. Injury. Injury which might occur during induction B. Bloat and Ventilation. The decrease in intestinal of anesthesia as a result of an awkward fall from standing motility which results from atropine administration, position to recumbency can be avoided by first casting the sedation, or general anesthesia permits gas from bacterial animal with ropes while muscle tone is still present. Tilting fermentation to accumulate. If food has not been withheld, surgical tables and rotating chutes also offer ideal means of distension of the rumen will be evident within one hour. The restraint. increased pressure of the rumen on the diaphragm severely The most frequent type of injury is forelimb lameness interferes with ventilation. The magnitude of this problem is which is manifested upon recovery from sedation or general illustrated in Figure 1 which depicts a three-month-old 100 anesthesia. The lameness is due to radial nerve damage kg Holstein calf which had been anesthetized for one hour and/or myositis caused by ischemia during the period of with only halothane in 100% oxygen. The animal had not recumbency. The clinical appearance of lameness due to been starved. Analysis of an arterial blood sample at this radial nerve damage is illustrated in Figure 3. A 310 kg time showed a pH 7.14, pCO 2 75 mmHg and pO 2 86 Holstein bull was anesthetized for one and one-half hours in mmHg. Normal values are pH 7.40, pCO 2 40 mmHg and right lateral recumbency for radiography with thiopental pO 2 500-600 mmHg. Thus the animal had a severe and halothane. Upon recovery, the bull was unable to extend respiratory acidosis and the oxygen level, although the forelimb and had lost conscious proprioception of the adequate, was dramatically below the value normally foot. The limb was unable to bear weight during the expected on 100% oxygen. This degree of ventilatory following 36 hours. Damage to the radial nerve usually embarrassment may have resulted in death of the animal due occurs where the nerve passes around the shoulder joint or to hypoxia if it had been breathing air (21% oxygen). lies in the musculo-spiral groove of the humerus. Myositis Recommendations: To prevent or reduce the incidence invariably involves the triceps brachii muscles but may also of bloat and impaired ventilation, food should be withheld include the deltoideus, pectoral, or brachchiocephalicus for 36 hours. muscles. Clinical experience indicates that a high incidence Treatment: It is important to prevent bloat occurring of radial nerve damage and/or myositis exists when an since passage of a stomach tube rarely achieves successful
Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical

    The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical

    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
  • Serum Progesterone Concentrations in Cows Receiving Embryo Transfers J

    Serum Progesterone Concentrations in Cows Receiving Embryo Transfers J

    Serum progesterone concentrations in cows receiving embryo transfers J. F. Hasler, R. A. Bowen, L. D. Nelson and G. E. Seidel, Jr Animal Reproduction Laboratory, Colorado State University, Fort Collins, Colorado 80523, U.SA. Summary. Progesterone concentrations in systemic blood were determined by radio- immunoassay in crossbred cattle used as recipients in an embryo transfer pro- gramme. An embryo was transferred surgically to the uterine horn of 528 females which were in oestrus within one half-day of the donor. Jugular blood was obtained at the time embryos were transferred (3\p=n-\7days after oestrus) and again from most females between Days 9 and 14. Pregnancy was determined by rectal palpation 45\p=n-\ 65 days after oestrus. There were no significant differences between serum pro- gesterone levels of females which remained pregnant and those which did not. Out of 177 pregnant recipients, none had serum progesterone levels <0\m=.\5ng/ml on Days 10, 11, or 12 but in 8, values were <1\m=.\0ng/ml. Blood samples were also taken on Days 20, 21, or 22 from 113 of these recipients. The mean \m=+-\s.e.m. concentration of progesterone in the pregnant females (5\m=.\14\m=+-\0\m=.\34ng/ml) was significantly higher (P < 0\m=.\001)than in the non-pregnant females (1\m=.\17\m=+-\0\m=.\25ng/ml). The correlation coefficients between progesterone levels on Days 3, 4, 5 or 6 and 10\p=n-\12ranged from 0\m=.\18to 0\m=.\37(all P < 0\m=.\02).Progesterone levels were not related to length of the previous cycle, the time of day an animal was first noticed in oestrus or the side of the corpus luteum.
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • INTRAVENOUS ANAESTHESIA Dr

    INTRAVENOUS ANAESTHESIA Dr

    INTRAVENOUS ANAESTHESIA Dr. SK Sharma, Associate Professor General anaesthesia: It is the controlled, reversible intoxication of CNS producing unconsciousness with complete loss of sensory as well as motor reflexes. The common methods to induce GA in animals are by using inhalation and intravenous anaesthesia. The other not so common methods are oral. Per rectal, intramuscular, intra peritoneum etc. However out of these methods the most preferred method is intravenous anaesthesia. Intravenous anaesthesia: Intravenous anaesthesia in veterinary practice is primarily used for the induction of anaesthesia which is subsequently maintained by inhalation anaesthesia in small animals. However in large animals intravenous anaesthesia is mostly used for both induction as well as maintenance of anaesthesia. Advantages: 1. Easiness in administration. 2. Produces surgical anaesthesia with speed and pleasantness. 3. No sophisticated facilities are required as for inhalation anaesthesia. 4. Requires minimum equipment. 5. Economical Disadvantages: 1. Recovery depends upon the ability of the animal to redistribute, metabolize and excrete the anaesthetic drug. Very important in sick and debilitatedDr. animals. SK Sharma 2. Depth of anaesthesia cannot be decreased quickly unless you have an antagonist. 3. Recovery period may be longer depending upon the health status of the animal and the drug used. 4. Characteristic excitement and premature attempts to stand during recovery may be dangerous sometimes. 5. Long procedures can lead to severe physiological changes in the patient. 6. Oxygen and assisted controlled ventilation may not be available during emergency. 2 RUMONANTS ARE POOR SUBJECTS FOR INTRAVENOUS ANAESTHESIA. WHY? The ruminants are considered as poor subjects for general anaesthesia by any method because of many reasons as listed below: 1.
  • Physiological Factors Affecting Ovine Uterine Estrogen and Progesterone Receptorconcentrations Redacted for Privacy Abstract Approved: W-A Fredrick Stormshak

    Physiological Factors Affecting Ovine Uterine Estrogen and Progesterone Receptorconcentrations Redacted for Privacy Abstract Approved: W-A Fredrick Stormshak

    AN ABSTRACT OF THE THESIS OF Patrice L. Prater for the degree of Master ofScience in Animal Science presented on November 14. 1990 Title: Physiological Factors Affecting Ovine Uterine Estrogen and Progesterone ReceptorConcentrations Redacted for Privacy Abstract Approved: w-A Fredrick Stormshak Two experiments were conducted todetermine whether in ewes uterine concentrationsof estrogen and progesterone receptors are affected by the presence of aconceptus or by the hormonal milieu associated withextremes in photoperiod to which ewes are exposed. In Exp.1, nine mature ewes were unilaterally ovariectomized by removing an ovary bearing the corpusluteum (CL). The ipsilateral uterine horn wasligated at the external bifurcation and a portion of theanterior ipsilateral uterine horn was removed and assayed forendometrial nuclear and cytosolic concentrations of estrogenreceptor (ER) and progesterone receptor (PR) by exchange assays. After a recovery estrous cycle, ewes werebred to a fertile ram. On day 18 of gestation a 10 ml jugular bloodsample was collected for measurement of serum concentrationsof estradiol -178 (E2) and progesterone by radioimmunoassay. Ewes were relaparotomized on day 18 and the remaining uterine tissue was removed. Endometrium from both the pregnant and nonpregnant uterine horn was assayed for nuclear and cytosolic ER and PR concentrations. Nuclear and cytosolic ER concentrations on day 10 of the cycle were greater than in endometrium of gravid and nongravid uterine horns on day 18 of gestation (p<.01). Endometrial nuclear PR levels were also greater on day 10 of the cycle than in the pregnant (p<.05) and nonpregnant horn (p<.01) on day 18 of gestation. There were no differences in nuclear and cytosolic ER and PR concentrations between the pregnant and nonpregnant uterine horn on day 18.
  • The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest

    The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest

    University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses 5-21-2004 The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest Donna Neumann University of New Orleans Follow this and additional works at: https://scholarworks.uno.edu/td Recommended Citation Neumann, Donna, "The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest" (2004). University of New Orleans Theses and Dissertations. 1040. https://scholarworks.uno.edu/td/1040 This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. THE DESIGN AND SYNTHESIS OF NOVEL BARBITURATES OF PHARMACEUTICAL INTEREST A Dissertation Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Donna M. Neumann B. A. University of New Orleans, 2000 May 2004 Dedicated to: My daughter, Madeline Megan Jenkins ii ACKNOWLEDGEMENTS I would like to express my utmost gratitude to my advisor, Professor Branko S.
  • Akhtar Saeed Medical and Dental College, Lhr

    Akhtar Saeed Medical and Dental College, Lhr

    STUDY GUIDE PHARMACOLOGY 3RD YEAR MBBS 2021 AKHTAR SAEED MEDICAL AND DENTAL COLLEGE, LHR 1 Table of contents s.No Topic Page No 1. Brief introduction about study guide 03 2. Study guide about amdc pharmacology 04 3. Learning objectives at the end of each topic 05-21 4. Pharmacology classifications 22-59 5. General pharmacology definitions 60-68 6. Brief introduction about FB PAGE AND GROUP 69-70 7. ACADEMIC CALENDER (session wise) 72 2 Department of pharmacology STUDY GUIDE? It is an aid to: • Inform students how student learnIng program of academIc sessIon has been organized • help students organIze and manage theIr studIes throughout the session • guIde students on assessment methods, rules and regulatIons THE STUDY GUIDE: • communIcates InformatIon on organIzatIon and management of the course • defInes the objectIves whIch are expected to be achIeved at the end of each topic. • IdentIfIes the learning strategies such as lectures, small group teachings, clinical skills, demonstration, tutorial and case based learning that will be implemented to achieve the objectives. • provIdes a lIst of learnIng resources such as books, computer assIsted learning programs, web- links, for students to consult in order to maximize their learning. 3 1. Learning objectives (at the end of each topic) 2. Sources of knowledge: i. Recommended Books 1. Basic and Clinical Pharmacology by Katzung, 13th Ed., Mc Graw-Hill 2. Pharmacology by Champe and Harvey, 2nd Ed., Lippincott Williams & Wilkins ii. CDs of Experimental Pharmacology iii. CDs of PHARMACY PRACTICALS iv. Departmental Library containing reference books & Medical Journals v. GENERAL PHARMACOLOGY DFINITIONS vi. CLASSIFICATIONS OF PHARMACOLOGY vii.
  • Administrative Records, Texas Department of Criminal Justice

    Administrative Records, Texas Department of Criminal Justice

    Consistent with the terms of the Court’s May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug’s supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA’s review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas’s redactions that are over-broad or otherwise improper, we will work with Texas’s counsel to revise the redactions in the record. MISCELLANEOUS FDA 568 DOCUMENT#: VERSION#: DIOP PROCEDURE ~L ORO-DIOP- 2.00 FOOD & DRUG ADMINISTRATION .008 I OFFICE OF REGULATORY AFFAIRS PAGE 1 OF 4 TITLE: EFFECTIVE DATE: PROCESSING OF SODIUM THIOPENTAL ENTRIES 4/16/2012 Sections included in this document 1. Purpose 2. Scope 3. Responsibility 4. Background 5. References 6. Procedure 7. Definitions/Glossary 8. Records 9. Supporting Documents 10. Contact Information 11.Attachments Document History and Change History 1. Purpose Pending litigation, this procedure provides instructions on the handling of shipments of Sodium Thiopental by Districts and the responsibility of DIOP in the processing of Sodium Thiopental entries. Districts should disseminate this information to all pertinent staff handling these entries.
  • FDA Briefing Document November 15, 2018

    FDA Briefing Document November 15, 2018

    FDA Briefing Document Anesthetic and Analgesic Drug Products Advisory Committee Meeting November 15, 2018 DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought background information related to assessment of opioid analgesic sparing outcomes in clinical trials of acute pain and the need to focus on the development of opioid sparing and opioid replacement drugs, which have potential to reduce the need for and use of opioid analgesics, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered. The final determination may be affected by issues not discussed at the advisory committee meeting. FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Anesthetic and Analgesic Drug Products Advisory Committee Meeting November 15, 2018 Table of Contents Background Materials Page 1 Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Director 1 Memorandum (Dr. Hertz) 2 Background information for Opioid Sparing 3 3 Appendix 1.
  • Guidance for Ideal Selection Tiffany Sia, MD; Hye-Chun Hur, MD, MPH

    Guidance for Ideal Selection Tiffany Sia, MD; Hye-Chun Hur, MD, MPH

    MDEDGE.COM/OBGYN | VOL 32, NO 10 | OCTOBER 2020 Society of Gynecologic Surgeons Annual Meeting Highlights Issue “Elective” should not be a descriptor for important ObGyn procedures Robert L. Barbieri, MD Update on contraception A member of the Network SPECIMEN RETRIEVAL BAGS Guidance for ideal selection Tiffany Sia, MD; Hye-Chun Hur, MD, MPH Work-life balance in gyn surgery Urethral bulking agents for SUI Should we abandon breast cancer screening for average-risk women in their 40s? only at mdedge.com/obgyn Optimizing coordination for dense breast screening p. 20 Follow us on Facebook and Twitter Improve Recovery After C-Section With Long-Lasting, Non-Opioid Pain Control Multimodal pain management with EXPAREL provided significantly better pain control after C-section vs multimodal protocols alone1,2 and… REDUCED REDUCED time REDUCED 52% postsurgical to ambulation vs hospital LOS by 1 day opioid use* (MED) over 12 multimodal protocol day (P<0.001); 2.9 days (n=97) 72 hours vs standard bupivacaine hours without EXPAREL 1 vs 3.9 days (n=89)1‡ TAP block (P=0.0117)2† (P<0.001)1‡ Improve clinical and economic outcomes. Learn more at www.EXPAREL.com/OBGyn LOS, length of stay; MED, morphine equivalent dose; TAP, transversus abdominis plane. *The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials. †A prospective, 13-site, multicenter, randomized clinical trial of 186 patients who underwent a C-section with a multimodal pain management protocol, including a TAP block using either 20 mL EXPAREL 266 mg, 20 mL 0.25% bupivacaine HCl, and 20 mL normal saline (30 mL volume on each side) for a total volume of 60 mL; or 20 mL 0.25% bupivacaine HCl and 40 mL normal saline (30 mL volume on each side) for a total volume of 60 mL.2,3 ‡Single-center retrospective trial of 201 patients who underwent C-section with either a multimodal pain management protocol including a TAP block with 20 mL EXPAREL 266 mg, 30 mL 0.25% bupivacaine HCI, and 30 mL normal saline; or a multimodal pain management protocol alone.